Tip os
Log ind
Bærbar scanner.jpg
Foto: DTU

New technology could revolutionize medtech firm’s business

Top picks in English:

Through the biggest project ever from Innovation Fund Denmark, researchers have developed an ultrasound scanning technology with the potential to transform the market. A medtech company involved in the project is now trying to figure out how to commercialize the invention.


BY LOUISE WENDT JENSEN
Offentliggjort 14.03.17 kl. 13:31

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

MSD fined for employee’s LinkedIn post

linkedin.jpg Top picks in English:

Sharing product-related news on the social media LinkedIn had consequences for an employee in the Danish unit of MSD. The post could be regarded as advertisement and has resulted in a fine from The Ethical Committee for the Pharmaceutical Industry.

Danish biotech company sold to Swedes

Top picks in English:

The Swedish company Ascelia, managed by a former Sunstone director, has acquired the biotech company Oncoral and its cancer candidate, which is currently being tested in phase I trials at Herlev Hospital in Denmark.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Gubra enters million-dollar agreement with big pharma

Top picks in English:

The Danish biotech company Gubra has announced a collaboration with a major German drug group for the development of novel peptide compounds. The deal has a potential value of EUR 250 million or approximately DKK 2 billion.

Leo Pharma announces new results for biologic hope

Top picks in English:

New phase III data from a study of one of Leo Pharma’s biologic drugs, Kyntheum, show significant benefits from long-term treatment with the drug.

Sweden saves quarter of a billion on MS medicine each year

Top picks in English:

By using off-label medicine that is cheaper – and according to doctors more effective – the Swedish health care system saves just over a quarter of a billion Swedish kronor on its bill for sclerosis medicine every year.

Forsiden lige nu

MedWatch-indeks: Oprejsning til hårdt prøvet biotekselskab

På vej op.jpg Medicinal & Biotek:

Bavarian Nordic-aktien har rejst sig en smule efter sidste uges nedtur, mens sidste uges taber, Onxeo, også i denne uge er i bunden af MedWatch-indekset.

CAR-T-selskab vil hente to milliarder

Medicinal & Biotek:

Amerikanske Juno Therapeutics vil sælge nye aktier og i yderste instans rejse, hvad der svarer til små 2 mia. kr. Samtidig er man rykket i et nyt hovedkvarter forud for en forventet godkendelse af sin CAR-T-cellebehandling til næste år.

Analytiker tror på snarlig milliardordre til Bavarian Nordic

Medicinal & Biotek:

De amerikanske myndigheder vil i løbet de kommende uger lægge ordre til knap 4,4 mia. kroner hos Bavarian Nordic, mener Jyske Banks analytiker.

41 stater sagsøger fem opioid-producenter

Medicinal & Biotek:

Statsadvokaterne i 41 amerikanske stater er gået sammen om at sagsøge fem producenter af de smertestillende midler, der går under fællesbetegnelsen opioider.

ALK-topchef: Det kan ikke sammenlignes med Stallergenes

Medicinal & Biotek:

Produktions-problemerne på en fransk fabrik vil kun have en meget begrænset effekt på ALK's forretning og kan ikke sidestilles med den franske Rival Stallergenes' produktionskvaler i 2016, siger adm. direktør Carsten Hellmann. Det danske selskab er allerede i gang med en omfattende opgradering af kvalitetskontrol og compliance i sit globale produktionsapparat.

Analytiker: Bavarian-flop var ikke en overraskelse

Medicinal & Biotek:

Markedet burde ikke have været chokeret, da Bavarian Nordics Prostvac-forsøg fejlede, mener analytiker Peter Aabo. For forsøget har været stillet forkert op fra start.

ANNONCE
ANNONCE


ANNONCE